Novavax vaccine was approved this week by the WHO, the organization writes in a press release.
It is the ninth vaccine to receive the green light from the WHO.
Parts of the production are located in Uppsala, which SVT previously reported on.
Sweden has booked four million doses of the vaccine via the EU, which has long had a contract with the pharmaceutical company.
Manufacturing problems and delays in clinical studies have meant that the vaccine has not yet started to be used, Sweden's vaccine coordinator Richard Bergström tells SVT Nyheter.
- We had expected that it would come already in the spring.
I expect approval from the EU on Monday, then we should in principle be able to access doses at once.
But since they had manufacturing problems, I'm not entirely sure - we'm lucky maybe they show up after New Year's.
Important for global vaccine supply
Covax, the WHO's fair distribution program for vaccine doses, has booked one billion doses.
For the supply of vaccines globally, the addition of Novax protein vaccine is "incredibly important", says Bergström.
In Sweden, next year it will continue to be Moderna and Pfizer that are the dominant covid vaccines.
- This is a protein vaccine, it has a slightly different approach than the mRNA vaccine.
It is a bit more proven but more difficult to update and manufacture.
We need different types of vaccines.
There are those who do not want to take the mrna vaccine and those who do not get enough antibody response, so it is a welcome addition, says Richard Bergström.